Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Sucampo Amitiza launch squeezes $10m milestone out of Takeda

This article was originally published in Scrip

Executive Summary

Maryland, US-based biopharmaceutical company, Sucampo Pharmaceuticals has received a $10m milestone payment from its collaborative partner, Takeda Pharmaceutical on the launch of Amitiza in the US for another indication.

You may also be interested in...



Accessing CAR-T Therapies

Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.

Taking Aim At Advanced Therapies

Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.

C-Suite Snippets: Conducting Due Diligence In Era Of Accelerated Science

In the most recent installment of In Vivo's VC Playbook column, former Amgen R&D lead Sean Harper talks exclusively about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021874

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel